Monday, February 5, 2024

vaccine to treat early bowel cancer -

  

20 Jul 2021 — “This PBS listing of KEYTRUDA is the first immunotherapy to be subsidised for bowel cancer patients living with this rare subtype of bowel ...
by A Kalyan2018Cited by 167 — Another approach to improve the immunogenicity of autologous vaccines in CRC utilizes autologous tumor cell vaccine modified by a non-lytic, low ...
by W Jia2022Cited by 19 — Figure 2 Various categories of colon cancer vaccines and their mechanisms. Dendritic cell (DC) vaccines utilize DCs loaded with tumor antigens ...
Missing: AUSTRALIAN ‎| Show results with: AUSTRALIAN
9 Jan 2017 — In 2006, the TGA approved Gardasil, and only a year later, Australia became the first country that rolled out a national HPV vaccination program ...
Missing: COLON ‎| Show results with: COLON
by L Au2021Cited by 84 — We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)—the Pfizer-BioNTech mRNA COVID-19 vaccine—in a patient ...
Colorectal cancer (CRC) is one of the most common ... This is an Earmarked scholarship project that aligns with a recently awarded Australian Government grant.
Bowel Cancer Australia is the leading community-funded charity dedicated to prevention, early diagnosis, research, quality treatment and care for everyone ...

Dr Tony Dhillon
Dr Tony Dhillon, a Consultant Medical Oncologist at the Royal Surrey NHS Foundation Trust, proposed the idea for the trial and has worked with Professor Tim Price in Australia for the last four years to develop the vaccine.

This is ground-breaking: British Indian doctor on new cancer vaccine

This is ground-breaking: British Indian doctor on new cancer vaccine

Dr Tony Dhillon, Consultant Medical Oncologist with the Royal Surrey NHS Foundation Trust, is the chief investigator behind a worldwide trial of a pre-surgery vaccine that he says has the potential to treat early bowel cancer. The British Indian doctor is the one who proposed the idea for the trial and has worked with Professor Tim Price in Australia for the last four years to develop the vaccine.

Dr Dhillon said: “This is the first treatment vaccine in any gastrointestinal cancer and we have high hopes that it will be very successful. We think that for a lot of patients, the cancer will have gone completely after this treatment.

“This is ground-breaking. I feel as if we are on the edge of something really big here. The vaccine makes the immune system go after the cancer. It will be life changing because it means that potentially, patients may not need to have surgery – they may just have the vaccine.
“The work we have done here at Royal Surrey is fantastic. We are hugely proud to have been involved in this worldwide trial and believe it could be key to treating bowel cancer in the future.”

The vaccine will be used to treat patients before surgery, in the hope that it will cause the body to attack the cancer. It would mean any surgery would be less invasive. It is also hoped that the strength of the vaccine could support the immune system to respond if there is a relapse and the cancer returns later on.

Patients will have an endoscopy, then a tissue sample will be tested to see if they are eligible for the trial. If they are, they will have three doses of the vaccine before having surgery to remove the cancer.

MORE LIKE THIS…

This is ground-breaking: British Indian doctor on new cancer vaccine
British Indian medic who raised alarms on killer nurse speaks of ‘nightmares’ of baby murders

The trial will be available for just 44 patients around the world. After the trial finishes, the vaccine – designed by Imugene Ltd – will either be licensed for use, or if it’s successful, a bigger study will be carried out.

The Royal Surrey National Health Service (NHS) Chief Executive Louise Stead said: “We are hugely proud to have been involved in the launch of this ground-breaking new vaccine.

“As the fourth-largest cancer centre in the UK, helping to fight cancer is a huge part of what we do and this will really provide an opportunity for bowel cancer patients and give them real hope of beating the disease.

“I would like to say a huge well done to Dr Tony Dhillon and everyone associated with this trial for all their hard work.”

MORE LIKE THIS…

This is ground-breaking: British Indian doctor on new cancer vaccine
Parliamentary Awards mark NHS 75th anniversary celebrations

The trial will be run by the Cancer Research UK Southampton Clinical Trials Unit at the University of Southampton in collaboration with the NHS trust and Queen Elizabeth Hospital in Adelaide, Australia. There will be 10 sites for patients to be enrolled – six in Australia and four in the UK, with 44 patients to be enrolled in the study over an 18-month period.

Bowel cancer, also known as colorectal cancer, is the third most common cancer, with a worldwide annual incidence of over 1.2 million cases and a mortality rate of approximately 50 per cent.




AI overview

Generative AI is experimental. Learn more
Listen
Your medical provider can give guidance on what is best for your situation. This information does not constitute medical advice or diagnosis. 
Mayo Clinic researchers are studying vaccines to treat and prevent cancer. They are researching vaccines to treat and prevent breast cancer, ovarian cancer, and other types of cancer. 
Cancer vaccines are similar to vaccines for infectious diseases like the flu, measles, mumps, and COVID. Cancer vaccines are a type of immunotherapy, which is a type of cancer treatment that boosts the body's immune system to fight cancer. 
Unlike vaccines to protect against disease, cancer treatment vaccines are for people who already have cancer. Cancer vaccines help the body's immune system recognize and attack cancer cells. 
Cancer vaccines illuminate more personalized treatment and ...
20 Oct 2022
Mayo Clinic
Vaccines to treat cancer - Cancer Research UK
cancerresearchuk.org
What are Cancer Vaccines?
cancer.net
Cancer Vaccines - Discovery and Translation Labs
Mayo Foundation for Medical Education and Research
Cancer vaccines: How they work, what to ask your doctor
4 Feb 2023
Fortune
What is an anti-cancer vaccine?
What is the new vaccine for breast cancer?
Name of the cervical cancer vaccine
TREOS' Phase I clinical trial will investigate the safety, tolerability, and immunogenicity of a single dose of PolyPEPI1018 CRC Vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients with metastatic colorectal cancer.
Mayo Foundation for Medical Education and Research
https://www.mayo.edu › clinical-trials › diseases-conditions
Colon Cancer Clinical Trials - Mayo Clinic Research

No comments:

Post a Comment